Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib and Temozolomide in newly diagnosed glioblastoma
NCT03466450Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Mar 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glasdegib in glioblastoma (GBM), sponsored by Grupo Español de Investigación en Neurooncología. Started Mar 2018; status: completed.
02
Drugs
glasdegib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03466450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466450.